Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
Story summaryThe Wegovy pill showed more pronounced weight loss and less cumbersome side effects than Eli Lilly's rival pill that was approved this week, Novo Nordisk said Thursday.
Read at CNBCOpens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.